The company's revenue base has effectively evaporated, with quarterly figures falling to $12,200 in 2026Q1, while operating margins remain deeply distorted at -358.7%.
| Sales/Revenue | 14.34K | 3.19K | 133.99K | 645.18K | 933.72K | 105.03K | 0 | 0 | 0 | 0 |
| Revenue Growth % | -74.09% | -97.62% | -79.23% | -30.9% | 788.96% | - | - | - | - | - |
| Cost of Goods Sold | 11.48K | 2.93K | 627.47K | 756.84K | 766.78K | 77.98K | 17.77K | 0 | 0 | 0 |
| COGS % of Revenue | - | 91.61% | 468.32% | 117.31% | 82.12% | 74.24% | - | - | - | - |
| Gross Profit | 2.85K | 268 | -493K | -111.66K | 166.94K | 27.05K | -17.77K | 0 | 0 | 0 |
| Gross Margin % | 19.89% | 8.39% | -367.95% | -17.31% | 17.88% | 25.76% | - | - | - | - |
| Gross Profit Growth % | - | 100.05% | -341.52% | -166.89% | 517.02% | 252.23% | - | - | - | - |
| Operating Expenses | 18.33M | 19.57M | 27.37M | 25.95M | 25.65M | 41.96M | 8.85M | 5.87M | 5.61M | 212.99K |
| OpEx % of Revenue | - | 612550.61% | 20427.66% | 4022.28% | 2746.77% | 39950.87% | - | - | - | - |
| Selling, General & Admin | 15.3M | 16.38M | 16.48M | 18.88M | 17.84M | 22.42M | 7.92M | 5.7M | 5.08M | 212.99K |
| SG&A % of Revenue | - | 512577.75% | 12302.87% | 2925.78% | 1910.11% | 21344.52% | - | - | - | - |
| Research & Development | 3.03M | 3.19M | 10.89M | 7.07M | 7.27M | 5.04M | 937.97K | 175.44K | 525K | 0 |
| R&D % of Revenue | - | 99972.86% | 8124.79% | 1096.5% | 778.4% | 4801.3% | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 544.03K | 14.5M | 0 | 0 | 0 | 0 |
| Operating Income | -18.32M | -19.57M | -27.86M | -26.06M | -25.48M | -41.94M | -8.87M | -5.87M | -5.61M | -213K |
| Operating Margin % | -127821.37% | -612542.22% | -20796.36% | -4039.58% | -2728.88% | -39925.17% | - | - | - | - |
| Operating Income Growth % | - | 29.76% | -6.91% | -2.29% | 39.24% | -372.66% | -51.12% | -4.67% | -2533.33% | - |
| EBITDA | -18.07M | -19.3M | -27.25M | -25.52M | -24.94M | -41.46M | -8.85M | 0 | 0 | 638.94K |
| EBITDA Margin % | -126063.3% | -604010.02% | -20335.67% | -3955.49% | -2671.48% | -39471.76% | - | - | - | - |
| EBITDA Growth % | 15.52% | 29.17% | -6.77% | -2.31% | 39.83% | -368.23% | - | - | -100% | - |
| D&A (Non-Cash Add-back) | 252.04K | 272.6K | 617.25K | 542.58K | 535.98K | 476.24K | 17.77K | 5.87M | 5.61M | 851.94K |
| EBIT | -50.94M | -40.4M | -27.66M | -26M | -25.36M | -44.43M | -8.84M | -5.83M | -5.61M | -213K |
| Net Interest Income | -1.82M | -2.19M | -7.36M | -6.38M | -2.23M | -1.94M | -309.52K | 0 | 0 | 0 |
| Interest Income | 200.17K | 200.18K | 1.45K | 10.17K | 57.35K | 3.1K | 563 | 1.93K | 0 | 0 |
| Interest Expense | 2.08M | 2.39M | 7.36M | 6.39M | 2.29M | 1.94M | 310.08K | 1.93K | 79.77K | 0 |
| Other Income/Expense | -34.7M | -23.22M | -7.16M | -6.33M | -2.17M | -4.44M | -277.02K | 43.07K | -79.77K | 0 |
| Pretax Income | -53.02M | -42.79M | -35.02M | -32.39M | -27.65M | -46.37M | -9.15M | -5.83M | -5.69M | -852K |
| Pretax Margin % | -369864.52% | -1339187.57% | -26137.25% | -5020.4% | -2961.29% | -44148.56% | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -852K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 100% |
| Net Income | -51.95M | -41.71M | -34.45M | -32.38M | -27.65M | -46.37M | -9.15M | -5.83M | -5.69M | -213K |
| Net Margin % | -362385.72% | -1305608.79% | -25708.85% | -5018.92% | -2961.29% | -44148.56% | - | - | - | - |
| Net Income Growth % | -104.32% | -21.1% | -6.38% | -17.11% | 40.37% | -406.83% | -56.94% | -2.47% | -2570.89% | - |
| Net Income (Continuing) | -53.02M | -42.79M | -35.02M | -32.39M | -27.65M | -46.37M | -9.15M | -5.83M | -5.69M | -213K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | -1.9M | -1.66M | -583.18K | -9.61K | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2575.18 | -1153.83 | -3062.42 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Growth % | -1269.9% | 62.32% | - | - | - | - | - | - | - | - |
| EPS (Basic) | - | -1153.83 | -3062.42 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Diluted Shares Outstanding | 20.17K | 37.35K | 13.18K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic Shares Outstanding | 20.17K | 37.35K | 11.25K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
Imminent insolvency and dilution
As indicated by the company's recent financial disclosures, quarterly revenue has plummeted to a negligible $12,200, representing a near-total collapse from historical levels and signaling that the firm's diagnostic product line has failed to achieve any meaningful or sustainable commercial traction in the current market.
The consistent, multi-quarter decline in top-line performance suggests that the diagnostic segment is no longer a viable engine for growth. Investors should interpret this trajectory as a transition from a commercial-stage entity to a pre-revenue research shell, where future revenue potential remains entirely speculative.
According to the provided income statement data, Aditxt's gross margin has exhibited extreme volatility, frequently dipping into negative territory, which underscores the fundamental inability of the current service-based diagnostic model to cover its direct costs of production or generate any meaningful contribution to overhead.
The erratic nature of these margins suggests a lack of pricing power and an inability to achieve economies of scale. This structural weakness implies that the current business model is fundamentally misaligned with the cost requirements of a biotechnology enterprise.
Based on reported figures, the company's operating margin of -612,542% highlights a massive disconnect between administrative overhead and revenue generation, suggesting that the firm's current cost structure is entirely disconnected from its actual operational output or any realistic path toward achieving future profitability.
The persistent reliance on high SG&A relative to near-zero revenue indicates that capital is being consumed primarily to maintain corporate existence rather than to drive clinical progress. This lack of operating leverage warrants significant concern regarding the sustainability of the current administrative footprint.
While the market may attempt to price Aditxt as a platform play for immune-tolerance IP, the financial data reveals a company with a cash-to-burn ratio that suggests an urgent need for dilutive financing, casting doubt on the viability of its long-term clinical development roadmap.
Short-term survival appears to be the primary challenge, as the current cash position is insufficient to support the high R&D and administrative costs required for clinical validation. Investors should monitor the risk of a total equity wipeout if the company fails to secure immediate, non-dilutive capital.
Quick answers to the most common questions about buying ADTX stock.
For fiscal year 2025, Aditxt, Inc. (ADTX) reported total revenue of $0.0M.
Aditxt, Inc. (ADTX) reported a net loss of $41.7M for the fiscal year ending 2025.
Aditxt, Inc. (ADTX) reported an operating income of $-19.6M, resulting in an operating profit margin of -612542.2%. This margin reflects the operational efficiency of the business before interest and taxes.
Aditxt, Inc. (ADTX) generated $0.0M in gross profit for the year, representing a gross profit margin of 8.4%. This demonstrates the company's core pricing power and production efficiency.